165 related articles for article (PubMed ID: 30403777)
21. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Morimura K; Yamamoto S; Murai T; Mori S; Chen TX; Wanibuchi H; Fukushima S
Carcinogenesis; 1999 Apr; 20(4):715-8. PubMed ID: 10223204
[TBL] [Abstract][Full Text] [Related]
22. Lack of change in the levels of liver and kidney cytochrome P-450 isozymes in p53+/- knockout mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Mori Y; Koide A; Fuwa K; Wanibuchi H; Fukushima S
Mutagenesis; 2001 Sep; 16(5):377-83. PubMed ID: 11507236
[TBL] [Abstract][Full Text] [Related]
23. Targeting glycogen metabolism in bladder cancer.
Ritterson Lew C; Guin S; Theodorescu D
Nat Rev Urol; 2015 Jul; 12(7):383-91. PubMed ID: 26032551
[TBL] [Abstract][Full Text] [Related]
24. [Mutation analysis of glycogen debrancher enzyme gene in five Chinese patients with glycogen storage disease type III].
Zhuang TF; Qiu ZQ; Wei M; Huang SZ
Zhonghua Er Ke Za Zhi; 2005 Feb; 43(2):85-8. PubMed ID: 15833157
[TBL] [Abstract][Full Text] [Related]
25. The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model.
Oliveira PA; Vasconcelos-Nóbrega C; Gil da Costa RM; Arantes-Rodrigues R
Methods Mol Biol; 2018; 1655():155-167. PubMed ID: 28889385
[TBL] [Abstract][Full Text] [Related]
26. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis.
Iida K; Itoh K; Kumagai Y; Oyasu R; Hattori K; Kawai K; Shimazui T; Akaza H; Yamamoto M
Cancer Res; 2004 Sep; 64(18):6424-31. PubMed ID: 15374950
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine.
Becci PJ; Thompson HJ; Grubbs CJ; Squire RA; Brown CC; Sporn MB; Moon RC
Cancer Res; 1978 Dec; 38(12):4463-6. PubMed ID: 719631
[TBL] [Abstract][Full Text] [Related]
28. Bladder carcinogenesis in mice induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and N-ethyl-N-(4-hydroxybutyl)-nitrosamine with reference to the effect of cyclophosphamide.
Numoto S; Yoshida M; Otsuka H
Gan; 1981 Oct; 72(5):647-54. PubMed ID: 7327366
[TBL] [Abstract][Full Text] [Related]
29. Clinical and genetic variability of glycogen storage disease type IIIa: seven novel AGL gene mutations in the Mediterranean area.
Lucchiari S; Fogh I; Prelle A; Parini R; Bresolin N; Melis D; Fiori L; Scarlato G; Comi GP
Am J Med Genet; 2002 May; 109(3):183-90. PubMed ID: 11977176
[TBL] [Abstract][Full Text] [Related]
30. Knockout of phospholipase Cε attenuates N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder tumorigenesis.
Jiang T; Liu T; Li L; Yang Z; Bai Y; Liu D; Kong C
Mol Med Rep; 2016 Mar; 13(3):2039-45. PubMed ID: 26782701
[TBL] [Abstract][Full Text] [Related]
31. Egyptian glycogen storage disease type III - identification of six novel AGL mutations, including a large 1.5 kb deletion and a missense mutation p.L620P with subtype IIId.
Endo Y; Fateen E; El Shabrawy M; Aoyama Y; Ebara T; Murase T; Podskarbi T; Shin YS; Okubo M
Clin Chem Lab Med; 2009; 47(10):1233-8. PubMed ID: 19754354
[TBL] [Abstract][Full Text] [Related]
32. Thioredoxin-interacting protein suppresses bladder carcinogenesis.
Nishizawa K; Nishiyama H; Matsui Y; Kobayashi T; Saito R; Kotani H; Masutani H; Oishi S; Toda Y; Fujii N; Yodoi J; Ogawa O
Carcinogenesis; 2011 Oct; 32(10):1459-66. PubMed ID: 21771725
[TBL] [Abstract][Full Text] [Related]
33. Commentary on "tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl) nitrosamine as the basis for urothelial cell carcinogenesis." He Z, Kosinska W, Zhao ZL, Wu XR, Guttenplan JB, Department of Basic Science, New York University Dental College, NY, USA.: Mutat Res 2012;742(1-2):92-5 [Epub 2011 Dec 4].
Scherr DS
Urol Oncol; 2014 Feb; 32(2):214. PubMed ID: 24445298
[TBL] [Abstract][Full Text] [Related]
34. Intron retention is among six unreported AGL mutations identified in Malaysian GSD III patients.
Abdullah IS; Teh SH; Khaidizar FD; Ngu LH; Keng WT; Yap S; Mohamed Z
Genes Genomics; 2019 Aug; 41(8):885-893. PubMed ID: 31028654
[TBL] [Abstract][Full Text] [Related]
35. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis.
Iida K; Itoh K; Maher JM; Kumagai Y; Oyasu R; Mori Y; Shimazui T; Akaza H; Yamamoto M
Carcinogenesis; 2007 Nov; 28(11):2398-403. PubMed ID: 17602169
[TBL] [Abstract][Full Text] [Related]
36. Isolation and nucleotide sequence of human liver glycogen debranching enzyme mRNA: identification of multiple tissue-specific isoforms.
Bao Y; Yang BZ; Dawson TL; Chen YT
Gene; 1997 Sep; 197(1-2):389-98. PubMed ID: 9332391
[TBL] [Abstract][Full Text] [Related]
37. Inorganic arsenic in drinking water accelerates N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tissue damage in mice.
Lin PY; Lin YL; Huang CC; Chen SS; Liu YW
Toxicol Appl Pharmacol; 2012 Feb; 259(1):27-37. PubMed ID: 22178741
[TBL] [Abstract][Full Text] [Related]
38. Effect of Schistosoma haematobium and N-butyl-N-(4-hydroxybutyl)nitrosamine on the development of urothelial neoplasia in the baboon.
Hicks RM; James C; Webbe G
Br J Cancer; 1980 Nov; 42(5):730-55. PubMed ID: 7459210
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of urinary bladder carcinogenesis in nullizygous p53-deficient mice by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Yamamoto S; Min W; Lee CC; Salim EI; Wanibuchi H; Sukata T; Fukushima S
Cancer Lett; 1999 Jan; 135(2):137-44. PubMed ID: 10096421
[TBL] [Abstract][Full Text] [Related]
40. Antiproliferative and anti-inflammatory properties of diindolylmethane and lupeol against N-butyl-N-(4-hydroxybutyl) nitrosamine induced bladder carcinogenesis in experimental rats.
Prabhu B; Balakrishnan D; Sundaresan S
Hum Exp Toxicol; 2016 Jun; 35(6):685-92. PubMed ID: 26251508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
